文献速递肝病

吗替麦考酚酯与他克莫司作为自身免疫性肝炎二线治疗的疗效与安全性

Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-06-08

该回顾性研究纳入欧洲、美国、加拿大和中国19个中心的201例自身免疫性肝炎患者,其中121例接受吗替麦考酚酯、80例接受他克莫司二线治疗,中位随访62个月。吗替麦考酚酯组与他克莫司组完全应答比例无显著差异(69.4% vs 72.5%,P=.639);对标准治疗不耐受的完全应答者中两药均能维持生化缓解;对标准治疗无应答者中他克莫司完全应答比例显著高于吗替麦考酚酯(56.5% vs 34%,P=.029)。

要点

  • 吗替麦考酚酯与他克莫司二线治疗自身免疫性肝炎的完全应答比例无显著差异(69.4% vs 72.5%,P=.639)。
  • 对标准治疗不耐受的完全应答者中,吗替麦考酚酯维持生化缓解91.9%、他克莫司94.1%(P=.682)。
  • 对标准治疗无应答者中,他克莫司完全应答比例显著高于吗替麦考酚酯(56.5% vs 34%,P=.029)。

核心结论

  • 吗替麦考酚酯或他克莫司长期治疗自身免疫性肝炎总体耐受良好。
  • 两药对既往对标准治疗不耐受的完全应答者疗效相当。
  • 对既往对标准治疗无应答的患者,他克莫司较吗替麦考酚酯获得完全应答的比例更高。

研究设计与样本

  • 回顾性研究,数据来自欧洲、美国、加拿大和中国19个中心的201例自身免疫性肝炎患者。
  • 121例接受吗替麦考酚酯、80例接受他克莫司二线治疗,中位随访62个月(范围6-190个月)。
  • 按对标准治疗的反应分组:第1组108例对标准治疗完全应答但因泼尼松(龙)或硫唑嘌呤副作用换用二线治疗;第2组93例对标准治疗无应答。

主要发现

  • 吗替麦考酚酯组完全应答69.4% vs 他克莫司组72.5%,无显著差异(P=.639)。
  • 第1组中吗替麦考酚酯维持生化缓解91.9% vs 他克莫司94.1%(P=.682)。
  • 第2组中他克莫司完全应答56.5% vs 吗替麦考酚酯34%,他克莫司较吗替麦考酚酯升高(P=.029)。
  • 肝病相关死亡或肝移植比例:吗替麦考酚酯组13.2% vs 他克莫司组10.3%(log-rank,P=.472)。
  • 因副作用需停药:吗替麦考酚酯组10例(8.3%)vs 他克莫司组10例(12.5%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Predniso(lo)ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH. METHODS: We performed a retrospective study of data (from 19 centers in Europe, the United States, Canada, and China) from 201 patients with AIH who received second-line therapy (121 received MMF and 80 received tacrolimus), for a median of 62 months (range, 6-190 mo). Patients were categorized according to their response to SOC. Patients in group 1 (n = 108) had a complete response to the SOC, but were switched to second-line therapy as a result of side effects of predniso(lo)ne or azathioprine, whereas patients in group 2 (n = 93) had not responded to SOC. RESULTS: There was no significant difference in the proportion of patients with a complete response to MMF (69.4%) vs tacrolimus (72.5%) (P = .639). In group 1, MMF and tacrolimus maintained a biochemical remission in 91.9% and 94.1% of patients, respectively (P = .682). Significantly more group 2 patients given tacrolimus compared with MMF had a complete response (56.5% vs 34%, respectively; P = .029) There were similar proportions of liver-related deaths or liver transplantation among patients given MMF (13.2%) vs tacrolimus (10.3%) (log-rank, P = .472). Ten patients receiving MMF (8.3%) and 10 patients receiving tacrolimus (12.5%) developed side effects that required therapy withdrawal. CONCLUSIONS: Long-term therapy with MMF or tacrolimus generally was well tolerated by patients with AIH. The agents were equally effective in previous complete responders who did not tolerate SOC therapy. Tacrolimus led to a complete response in a greater proportion of previous nonresponder patients compared with MMF.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Efe C, Hagström H, Ytting H, et al. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2017. PMID: 28603052. doi:10.1016/j.cgh.2017.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。